Chimeric antigen receptor T-cell therapy for T-ALL and AML
Non-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of existing treatments for refractory or relapsed (R/R) non-B-cell acute leukemia is limited. In such situations, chimeric antig...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.967754/full |
| _version_ | 1798016487569489920 |
|---|---|
| author | Wenwen Wei Wenwen Wei Dong Yang Xi Chen Dandan Liang Liqun Zou Xudong Zhao |
| author_facet | Wenwen Wei Wenwen Wei Dong Yang Xi Chen Dandan Liang Liqun Zou Xudong Zhao |
| author_sort | Wenwen Wei |
| collection | DOAJ |
| description | Non-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of existing treatments for refractory or relapsed (R/R) non-B-cell acute leukemia is limited. In such situations, chimeric antigen receptor (CAR)-T cell therapy may be a promising approach to treat non-B-cell acute leukemia, given its promising results in B-cell acute lymphoblastic leukemia (B-ALL). Nevertheless, fratricide, malignant contamination, T cell aplasia for T-ALL, and specific antigen selection and complex microenvironment for AML remain significant challenges in the implementation of CAR-T therapy for T-ALL and AML patients in the clinic. Therefore, designs of CAR-T cells targeting CD5 and CD7 for T-ALL and CD123, CD33, and CLL1 for AML show promising efficacy and safety profiles in clinical trials. In this review, we summarize the characteristics of non-B-cell acute leukemia, the development of CARs, the CAR targets, and their efficacy for treating non-B-cell acute leukemia. |
| first_indexed | 2024-04-11T15:51:21Z |
| format | Article |
| id | doaj.art-6e5c1dc9a3094af39bf42af80d3b0419 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T15:51:21Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6e5c1dc9a3094af39bf42af80d3b04192022-12-22T04:15:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.967754967754Chimeric antigen receptor T-cell therapy for T-ALL and AMLWenwen Wei0Wenwen Wei1Dong Yang2Xi Chen3Dandan Liang4Liqun Zou5Xudong Zhao6Laboratory of Animal Tumor Models, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Medical Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, ChinaLaboratory of Animal Tumor Models, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Radiotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu, ChinaLaboratory of Animal Tumor Models, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, ChinaDepartment of Medical Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, ChinaLaboratory of Animal Tumor Models, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, ChinaNon-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of existing treatments for refractory or relapsed (R/R) non-B-cell acute leukemia is limited. In such situations, chimeric antigen receptor (CAR)-T cell therapy may be a promising approach to treat non-B-cell acute leukemia, given its promising results in B-cell acute lymphoblastic leukemia (B-ALL). Nevertheless, fratricide, malignant contamination, T cell aplasia for T-ALL, and specific antigen selection and complex microenvironment for AML remain significant challenges in the implementation of CAR-T therapy for T-ALL and AML patients in the clinic. Therefore, designs of CAR-T cells targeting CD5 and CD7 for T-ALL and CD123, CD33, and CLL1 for AML show promising efficacy and safety profiles in clinical trials. In this review, we summarize the characteristics of non-B-cell acute leukemia, the development of CARs, the CAR targets, and their efficacy for treating non-B-cell acute leukemia.https://www.frontiersin.org/articles/10.3389/fonc.2022.967754/fullchimeric antigen receptorT-ALLAMLantigenimmunotherapy |
| spellingShingle | Wenwen Wei Wenwen Wei Dong Yang Xi Chen Dandan Liang Liqun Zou Xudong Zhao Chimeric antigen receptor T-cell therapy for T-ALL and AML Frontiers in Oncology chimeric antigen receptor T-ALL AML antigen immunotherapy |
| title | Chimeric antigen receptor T-cell therapy for T-ALL and AML |
| title_full | Chimeric antigen receptor T-cell therapy for T-ALL and AML |
| title_fullStr | Chimeric antigen receptor T-cell therapy for T-ALL and AML |
| title_full_unstemmed | Chimeric antigen receptor T-cell therapy for T-ALL and AML |
| title_short | Chimeric antigen receptor T-cell therapy for T-ALL and AML |
| title_sort | chimeric antigen receptor t cell therapy for t all and aml |
| topic | chimeric antigen receptor T-ALL AML antigen immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.967754/full |
| work_keys_str_mv | AT wenwenwei chimericantigenreceptortcelltherapyfortallandaml AT wenwenwei chimericantigenreceptortcelltherapyfortallandaml AT dongyang chimericantigenreceptortcelltherapyfortallandaml AT xichen chimericantigenreceptortcelltherapyfortallandaml AT dandanliang chimericantigenreceptortcelltherapyfortallandaml AT liqunzou chimericantigenreceptortcelltherapyfortallandaml AT xudongzhao chimericantigenreceptortcelltherapyfortallandaml |